Other JAK-STAT inhibitors are currently under investigation, such as tofacitinib and peficitinib, which are always employed and integrated into the chemotherapy backbone; in particular, NCT06128070 is a trial that highlights the potential of ruxolitinib together with tacrolimus and MTX for the prevention of graft versus host disease in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplant for not only ALL but also acute myeloid leukemia and myelodysplastic syndrome [96]. The gene discussed is SOAT1; the disease is acute lymphoblastic leukemia.